Hemispherx Biopharma Aktie [WKN DE: A2PREX / ISIN: US00901B1052]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Hemispherx Biopharma Inc Registered Shs

07.09.22		TRADE X Opens Its B2B Trading Platform to Automotive Buyers in the Dominican Republic (PR Newswire)
18.08.22		AIM ImmunoTech Commences Phase 2 Study Of Ampligen For Pancreatic Cancer Treatment (RTTNews)
18.08.22		AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer (GlobeNewswire)
28.07.22		AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID (GlobeNewswire)
20.07.22		AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free (GlobeNewswire)
18.07.22		AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid (GlobeNewswire)
14.07.22		AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series (GlobeNewswire)
13.06.22		AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Trea (GlobeNewswire)
21.04.22		AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies (GlobeNewswire)
11.04.22		AIM ImmunoTech Up 8% As Its Ampligen To Treat Breast Cancer Meets Primary Goal (RTTNews)
11.04.22		AIM ImmunoTech's Investigational Drug Meets Goal In Phase 1 Breast Cancer Study (RTTNews)
11.04.22		AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer (GlobeNewswire)
11.04.22		AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver (GlobeNewswire)
31.03.22		AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
28.03.22		AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress (GlobeNewswire)
16.03.22		AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
08.03.22		AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Can (GlobeNewswire)
24.01.22		AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer (GlobeNewswire)
16.11.21		AIM ImmunoTech Provides Third Quarter 2021 Business Update (GlobeNewswire)
19.10.21		AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer (GlobeNewswire)
04.10.21		AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer (GlobeNewswire)
30.09.21		AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses (GlobeNewswire)
08.09.21		AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction (GlobeNewswire)
17.08.21		AIM ImmunoTech Provides Second Quarter 2021 Business Update (GlobeNewswire)
13.08.21		Aimia Declares Preferred Share Dividends (PR Newswire)
13.08.21		Aimia Reports Second Quarter 2021 Results (PR Newswire)
27.07.21		B2B Automotive Trading Platform TRADE X Secures C$44 Million in New Equity Financing for Global Expansion (PR Newswire)
27.07.21		B2B Automotive Trading Platform TRADE X Secures C$44 Million in New Equity Financing for Global Expansion (PR Newswire)
27.07.21		B2B Automotive Trading Platform TRADE X Secures C$44 Million in New Equity Financing for Global Expansion (PR Newswire)
27.07.21		B2B Automotive Trading Platform TRADE X Secures C$44 Million in New Equity Financing for Global Expansion (PR Newswire)
27.07.21		Aimia Invests in TRADE X (PR Newswire)
09.07.21		AIM Immuno : Phase 2a Trial To Test Ampligen As Intranasal Antiviral Prophylactic Therapy (RTTNews)
09.07.21		AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy (GlobeNewswire)
28.06.21		Aimia completes sale of investment in BIGLIFE to AirAsia (PR Newswire)
17.06.21		Aimia Announces Normal Course Issuer Bid to Repurchase up to 7.3 Million Shares (PR Newswire)
14.06.21		AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2 (GlobeNewswire)
07.04.21		AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Oth (GlobeNewswire)
08.03.21		AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study (GlobeNewswire)
24.02.21		AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer (GlobeNewswire)
16.02.21		AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy (GlobeNewswire)
10.02.21		AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands (GlobeNewswire)
05.02.21		AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials (GlobeNewswire)
21.12.20		AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer (GlobeNewswire)
25.11.20		AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19 (GlobeNewswire)
14.05.20		Stock Alert: AIM ImmunoTech Shares Jump 30% In Premarket (RTTNews)
12.03.20		Stocks Double And Tripled In Value From Coronavirus (RTTNews)
11.02.20		AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus (GlobeNewswire)
25.09.19		Today's Top 5 Losers In Healthcare Sector (ECOR, NTEC, AIM...) (RTTNews)
20.09.19		6 Top Gainers In Healthcare Sector (AIM, EDSA, ARAV…) (RTTNews)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Nach NVIDIA & Co: Diese beiden Unternehmen könnten den nächsten Aktiensplit erleben

Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 2

APA - N A C H R I C H T E N Ü B E R B L I C K

Steinmeier setzt Neuwahlen für 23. Februar an

Konkurrenz für D-Wave Quantum: Auf diese Geschäftseinheit von Honeywell hält ein Analyst große Stücke

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.01.2025 19:44
Kaufwert:	EUR
	Hinzufügen Speichern